Acadia Pharmaceuticals Stock Performance
| ACAD Stock | USD 16.18 0.09 0.55% |
ACADIA Pharmaceuticals has a performance score of 1 on a scale of 0 to 100. The firm owns a Beta (Systematic Risk) of 1.66, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ACADIA Pharmaceuticals will likely underperform. ACADIA Pharmaceuticals at this moment owns a risk of 2.28%. Please confirm ACADIA Pharmaceuticals mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and total risk alpha , to decide if ACADIA Pharmaceuticals will be following its current price history.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in ACADIA Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound basic indicators, ACADIA Pharmaceuticals is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return 2.97 | Five Day Return (2.80) | Year To Date Return (46.01) | Ten Year Return (43.58) | All Time Return 148.66 |
1 | Acquisition by Brendan Teehan of 1107 shares of ACADIA Pharmaceuticals subject to Rule 16b-3 | 09/13/2024 |
2 | ACADIA HEALTHCARE INVESTOR ALERT ScottScott Attorneys at Law LLP Investigates Marathon Petroleum Corporations Directors and Officers for Breach of Fiduciary Dut... | 09/23/2024 |
3 | ACAD or TECH Which Is the Better Value Stock Right Now | 10/09/2024 |
4 | Disposition of 4381 shares by Ndu Adora of ACADIA Pharmaceuticals subject to Rule 16b-3 | 10/11/2024 |
5 | ACADIA HEALTHCARE SHAREHOLDER ALERT by Former Louisiana Attorney General Kahn Swick Foti, LLC Reminds Investors With Losses in Excess of 100,000 of Lead Plainti... | 10/21/2024 |
6 | ACADIA earnings beat by 0.06, revenue topped estimates | 11/06/2024 |
7 | Acadias Q3 Earnings Beat, Nuplazid Daybue Drive Revenue Growth | 11/07/2024 |
8 | ACADIA Pharmaceuticals Inc. Q3 2024 Earnings Call Transcript | 11/08/2024 |
9 | WCM Investment Management LLC Has 4.50 Million Holdings in ACADIA Pharmaceuticals Inc. | 11/12/2024 |
10 | ACADIA Pharmaceuticals Downgraded to Buy Rating by StockNews.com | 11/15/2024 |
11 | Disposition of 10259 shares by Mark Schneyer of ACADIA Pharmaceuticals at 16.81 subject to Rule 16b-3 | 11/19/2024 |
12 | ACADIA HEALTHCARE SHAREHOLDER ALERT CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF ... | 11/21/2024 |
| Begin Period Cash Flow | 114.8 M |
ACADIA |
ACADIA Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,609 in ACADIA Pharmaceuticals on August 24, 2024 and sell it today you would earn a total of 9.00 from holding ACADIA Pharmaceuticals or generate 0.56% return on investment over 90 days. ACADIA Pharmaceuticals is currently generating 0.0341% in daily expected returns and assumes 2.2842% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than ACADIA, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ACADIA Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ACADIA Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ACADIA Pharmaceuticals, and traders can use it to determine the average amount a ACADIA Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0149
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ACAD |
Estimated Market Risk
| 2.28 actual daily | 20 80% of assets are more volatile |
Expected Return
| 0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 1 99% of assets perform better |
Based on monthly moving average ACADIA Pharmaceuticals is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ACADIA Pharmaceuticals by adding it to a well-diversified portfolio.
ACADIA Pharmaceuticals Fundamentals Growth
ACADIA Stock prices reflect investors' perceptions of the future prospects and financial health of ACADIA Pharmaceuticals, and ACADIA Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ACADIA Stock performance.
| Return On Equity | 0.27 | ||||
| Return On Asset | 0.0872 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 2.19 B | ||||
| Shares Outstanding | 166.39 M | ||||
| Price To Earning | (13.77) X | ||||
| Price To Book | 4.69 X | ||||
| Price To Sales | 2.90 X | ||||
| Revenue | 726.44 M | ||||
| Gross Profit | 145.49 M | ||||
| EBITDA | (67.83 M) | ||||
| Net Income | (61.29 M) | ||||
| Cash And Equivalents | 436.35 M | ||||
| Cash Per Share | 2.70 X | ||||
| Total Debt | 57.2 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 4.53 X | ||||
| Book Value Per Share | 3.47 X | ||||
| Cash Flow From Operations | 16.7 M | ||||
| Earnings Per Share | 0.78 X | ||||
| Market Capitalization | 2.69 B | ||||
| Total Asset | 748.96 M | ||||
| Retained Earnings | (2.43 B) | ||||
| Working Capital | 361.87 M | ||||
| Current Asset | 603.49 M | ||||
| Current Liabilities | 39.15 M | ||||
About ACADIA Pharmaceuticals Performance
By analyzing ACADIA Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into ACADIA Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ACADIA Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ACADIA Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 285.89 | 153.81 | |
| Return On Tangible Assets | (0.09) | (0.09) | |
| Return On Capital Employed | (0.15) | (0.16) | |
| Return On Assets | (0.08) | (0.09) | |
| Return On Equity | (0.14) | (0.15) |
Things to note about ACADIA Pharmaceuticals performance evaluation
Checking the ongoing alerts about ACADIA Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ACADIA Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 726.44 M. Net Loss for the year was (61.29 M) with profit before overhead, payroll, taxes, and interest of 145.49 M. | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: ACADIA HEALTHCARE SHAREHOLDER ALERT CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF ... |
- Analyzing ACADIA Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ACADIA Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining ACADIA Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ACADIA Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ACADIA Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ACADIA Pharmaceuticals' stock. These opinions can provide insight into ACADIA Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ACADIA Stock analysis
When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |